Product Candidates

Within our IP patented portfolio are a host of potential applications for our peptides. These include the treatment of acute inflammatory diseases such as Acute Otitis Media (AOM), Systemic Inflammation, Meningitis, Traumatic Brain Injury (TBI), Uveitis and Ischemia. We are also evaluating peptides in chronic models for Lupus, Rheumatoid Arthritis (RA), Multiple Sclerosis, Atherosclerosis, Crohn’s Disease and Psoriasis, among others. Using our evolution-based methodology, we envision rapid development across several disease states.

P13 is the company's most advanced peptide and is being tested for treatment of Acute Otitis Media (AOM) and other inflammatory conditions. Other peptides are under evaluation for a variety of autoimmune and inflammatory diseases.